[January 27, 2015] |
|
CBI Pharma to Hold 6th Annual IVD Summit 2015 on March 12-13 in Shenzhen, China
CBI Pharma, a subsidiary of ENMORE, will hold the 6th
Annual IVD Summit 2015 (IVDS 2015) in Shenzhen,
China on March 12-13, 2015. As the No.1 IVD industry summit
in China, IVDS discusses industry policies and market trends and
provides a good cooperation and communication platform for IVD industry
players around the world.
China is the fastest increasing IVD market with a 16% average annual
growth rate. At the same time, with the enhancement of China's medical
insurance policy and its popularization in rural areas, public awareness
of medical treatment and healthcare will continue to rise. In the
meantime, with the rapid growth of national economy and improvement of
people's living standard, the demand for IVD products will be
sequentially increased. China's IVD market holds tremendous potential.
However, China is faced with many restrictions like outdated laws and
regulations, a low concentration rate for the industry, weak R&D
capacity, lack of talent, intense homogenized competition and so on. To
break the bottleneck, it's necessary to enhance cooperation and
communication among governments, manufacturers, institutions, end-users
and investors.
IVDS 2015 will explore and present scientific, pragmatic,
authoritative and up-to-date expertise and technologies to you. The
participants will have great networking opportunities and get a thorough
update about the policies and the market. Besides, cases will be studied
to demonstrate how cutting-edge technologies have been turned into
commercial success.
Topics to be covered include:
Development Tendency of IVD Industry during the "13th
Five-year Plan" Period in China Global IVD Industry and
Segment Market Analysis Market Opportunities of Wearable Medical
Equipment Application Tendency of Next-generation Sequencing Present
Situation and Outlook of Pediatric Infectious Disease Virus Reagents Present
Situation and Future Forecast on POCT Market in China Pharmacogenomics
and Individualized Therapy Performance Evaluation of IVD Products
[ Back To TMCnet.com's Homepage ]
|